kt 5823 has been researched along with tafluprost in 1 studies
| Studies (kt 5823) | Trials (kt 5823) | Recent Studies (post-2010) (kt 5823) | Studies (tafluprost) | Trials (tafluprost) | Recent Studies (post-2010) (tafluprost) |
|---|---|---|---|---|---|
| 317 | 0 | 59 | 151 | 35 | 113 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukuda, M; Kanamori, A; Naka, M; Nakamura, M; Negi, A | 1 |
1 other study(ies) available for kt 5823 and tafluprost
| Article | Year |
|---|---|
Tafluprost protects rat retinal ganglion cells from apoptosis in vitro and in vivo.
Topics: Animals; Apoptosis; Calcium; Calcium Channel Blockers; Carbazoles; Caspase 3; Cell Line; Cell Survival; Culture Media, Serum-Free; Cyclic GMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Glutamic Acid; In Vitro Techniques; Instillation, Drug; Intracellular Membranes; Intraocular Pressure; Male; Nerve Crush; Neuroprotective Agents; Ophthalmic Solutions; Optic Nerve; Prostaglandins F; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Retinal Ganglion Cells; Time Factors | 2009 |